Abstract Body: Introduction & Objective: Stroke care is fragmented with reported 30-day readmission rates as high as 10-15%. Novel, cost effective strategies to improve care coordination and address social determinants of care are needed. We sought to evaluate the clinical and financial impact of a home-based stroke care delivery model colloquially called Stroke Mobile (SM). Methods: Patients discharged to home, home health, rehab or skilled nursing facility followed by home from an Ochsner Health hospital in the New Orleans region between July 2021 through December 2022 with stroke (ischemic stroke, TIA, ICH) and on a value-based contract were eligible for the study. Patients were seen at home by an RN and health educator within 30 days of discharge followed by monthly for 3 consecutive months. Thereafter, patients were seen periodically as determined by the care team up to a year. Patients seen by the SM team were compared to a propensity matched control group comprising of patients eligible for care service by the SM team but not enrolled in the program during the study period. Propensity score matching was performed using age, gender, race and chronic conditions as covariates and “nearest neighbor” algorithm with 1:3 match ratio. Parametric (independent sample t-test) and non-parametric (Wilcoxon rank sum, Chi-square) tests were used to test the difference in overall cost (per member per month (pmpm)), 30-day readmissions, and cost of readmission between groups with an error rate set to <5% (p<0.05). Results: Two hundred and seven patients enrolled in SM (intervention group) and 621 eligible patients not enrolled (control group) . $833,760 annual cost savings was observed in the intervention group ($1,226pmpm vs. $1,612pmpm; Δ$386; p<0.05). Of note, significantly higher cost savings were seen within the first 90 days of the program ($764pmpm vs. $1,423pmpm; Δ$659; p<0.05). However, cost savings diminished by the second 90-day interval and plateaued by third and fourth intervals (Fig). No readmissions were observed in the intervention group compared to 2% readmissions with $29pmpm readmission cost in the control group ($0pmpm vs. $29pmpm; p=0.01). Conclusions: Our home-based, post-stroke, care delivery program (SM) is effective in reducing the overall costs within the first 180 days of enrollment with maximum benefit noted within the first 90 days. The readmission reduction the SM group did not reach statistical significance, possibly due to a type II error.